Search

Your search keyword '"Behre, Gerhard"' showing total 395 results
Start Over Author "Behre, Gerhard" Search Limiters Available in Library Collection
395 results on '"Behre, Gerhard"'

9. Characterization of postvaccination SARS-CoV-2 T cell subtypes in patients with different hematologic malignancies and treatments.

Author

Pfannes, Roald, Pierzchalski, Arkadiusz, Maddalon, Ambra, Simion, Alexandra, Zouboulis, Christos C., Behre, Gerhard, Zenclussen, Ana Claudia, Westphal, Sabine, Fest, Stefan, and Herberth, Gunda

Subjects
T cells, HEMATOLOGIC malignancies, COVID-19 vaccines, SARS-CoV-2, HEPATITIS B vaccines, CANCER vaccines, BCG vaccines
Abstract

Background: To evaluate the benefits of SARS-CoV-2 vaccination in cancer patients it is relevant to understand the adaptive immune response elicited after vaccination. Patients affected by hematologicmalignancies are frequently immune-compromised and show a decreased seroconversion rate compared to other cancer patients or controls. Therefore, vaccine-induced cellular immune responses in these patients might have an important protective role and need a detailed evaluation. Methods: Certain T cell subtypes (CD4, CD8, Tfh, γκT), including cell functionality as indicated by cytokine secretion (IFN, TNF) and expression of activation markers (CD69, CD154) were assessed via multi-parameter flow cytometry in hematologic malignancy patients (N=12) and healthy controls (N=12) after a second SARS-CoV-2 vaccine dose. The PBMC of post-vaccination samples were stimulated with a spike-peptide pool (S-Peptides) of SARS-CoV-2, with CD3/CD28, with a pool of peptides from the cytomegalovirus, Epstein-Barr virus and influenza A virus (CEF-Peptides) or left unstimulated. Furthermore, the concentration of spike-specific antibodies has been analyzed in patients. Results: Our results indicate that hematologic malignancy patients developed a robust cellular immune response to SARS-CoV-2 vaccination comparable to that of healthy controls, and for certain T cell subtypes even higher. The most reactive T cells to SARS-CoV-2 spike peptides belonged to the CD4 and Tfh cell compartment, being median (IQR), 3.39 (1.41-5.92) and 2.12 (0.55-4.14) as a percentage of IFN- and TNF-producing Tfh cells in patients. In this regard, the immunomodulatory treatment of patients before the vaccination period seems important as it was strongly associated with a higher percentage of activated CD4 and Tfh cells. SARS-CoV-2-and CEF-specific T cell responses significantly correlated with each other. Compared to lymphoma patients, myeloma patients had an increased percentage of SARS-CoV-2-specific Tfh cells. T-SNE analysis revealed higher frequencies of γκT cells in patients compared to controls, especially in myeloma patients. In general, after vaccination, SARS-CoV-2- specific T cells were also detectable in patients without seroconversion. Conclusion: Hematologic malignancy patients are capable of developing a SARS-CoV-2-specific CD4 and Tfh cellular immune response after vaccination, and certain immunomodulatory therapies in the period before vaccination might increase the antigen-specific immune response. A proper response to recall antigens (e.g., CEF-Peptides) reflects immune cellular functionality and might be predictive for generating a newly induced antigen-specific immune response as is expected after SARS-CoV-2 vaccination. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

14. Bamlanivimab and Etesevimab Improve Symptoms and Associated Outcomes in Ambulatory Patients at Increased Risk for Severe Coronavirus Disease 2019: Results From the Placebo-Controlled Double-Blind Phase 3 BLAZE-1 Trial

Author

Chen, Peter, primary, Behre, Gerhard, additional, Hebert, Corey, additional, Kumar, Princy, additional, Farmer Macpherson, Lisa, additional, Graham-Clarke, Peita Louise, additional, De La Torre, Inmaculada, additional, Nichols, Russell M, additional, Hufford, Matthew M, additional, Patel, Dipak R, additional, and Naegeli, April N, additional

Published
2022
Full Text
View/download PDF

15. Correction to: EVI2B is a C/EBPα target gene required for granulocytic differentiation and functionality of hematopoietic progenitors

Author

Zjablovskaja, Polina, Kardosova, Miroslava, Danek, Petr, Angelisova, Pavla, Benoukraf, Touati, Wurm, Alexander A., Kalina, Tomas, Sian, Stephanie, Balastik, Martin, Delwel, Ruud, Brdicka, Tomas, Tenen, Daniel G., Behre, Gerhard, Fiore, Fréderic, Malissen, Bernard, Horejsi, Vaclav, and Alberich-Jorda, Meritxell

Published
2019
Full Text
View/download PDF

21. The impact of G protein-coupled oestrogen receptor 1 on male breast cancer: a retrospective analysis

Author

Maiwald, Jan-Hendrik, primary, Sprung, Susanne, additional, Czapiewski, Piotr, additional, Lessel, Wiebke, additional, Scherping, Anna, additional, Schomburg, Dirk, additional, Plaumann, Markus, additional, Tomasik, Bartłomiej, additional, Behre, Gerhard, additional, Haybaeck, Johannes, additional, Ignatov, Atanas, additional, Eggemann, Holm, additional, and Nass, Norbert, additional

Published
2021
Full Text
View/download PDF

22. Case Report: Allogeneic Stem Cell Transplantation Following Induction With CPX-351 in Patients With Acute Myeloid Leukemia Is Feasible

Author

Vucinic, Vladan, Jentzsch, Madlen, Schwind, Sebastian, Bach, Enrica, Leiblein, Sabine, Remane, Yvonne, Rieprecht, Susanne, Otto, Sandra, Kubasch, Anne-Sophie, Behre, Gerhard, Cross, Michael, Platzbecker, Uwe, and Franke, Georg-Nikolaus

Subjects
CPX-351, induction therapy, Case Report, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lcsh:RC254-282, therapy-related acute myeloid leukemia, surgical procedures, operative, Oncology, hematopoeietic stem cell transplantation, hemic and lymphatic diseases, AML-MRC, ddc:610, CPX-351, AML-MRC, therapy-related acute myeloid leukemia, induction therapy, hematopoeietic stem cell transplantation, prognosis, prognosis
Abstract

Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) and treatment-related acute myeloid leukemia (tAML) after chemotherapy or radiation therapy for other neoplasms are associated with poor outcomes. CPX-351, a dual-drug liposomal encapsulation of daunorubicin and cytarabine, has been shown to improve outcomes in AML-MRC and tAML compared with standard 7+3 regimens. Here we report the cases of four consecutive patients with AML-MRC or tAML who received CPX-351 as outpatient induction therapy immediately followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT). Two patients received allo-HSCT in remission (one in complete remission and one in partial remission) and two patients received allo-HSCT in aplasia (one at 11 days and one at 52 days after the start of induction therapy with CPX-351). With a median follow-up of 188 days after allo-HSCT, all but one patient are alive and two are in remission. Further studies will help define and expand the role of CPX-351 in the treatment of AML-MRC and tAML, especially in patients expected to undergo allo-HSCT.

Published
2020

26. AML1-ETO downregulates the granulocytic differentiation factor C/EBP[alpha] in t(8;21) myeloid leukemia

Author

Pabst, Thomas, Mueller, Beatrice U., Harakawa, Nari, Schoch, Claudia, Haferlach, Torsten, Behre, Gerhard, Hiddemann, Wolfgang, Zhang, Dong-Er, and Tenen, Daniel G.

Abstract

The transcription factor CCAAT/enhancer binding protein [alpha], or C/EBP[alpha], encoded by the CEBPA gene, is crucial for the differentiation of granulocytes. Conditional expression of C/EBP[alpha] triggers neutrophilic differentiation, and Cebpa knockout mice exhibit an early block in maturation. Dominant-negative mutations of CEBPA have been found in some patients with acute myeloid leukemia (AML), but not in AML with the t(8;21) translocation which gives rise to the fusion gene RUNX1-CBF2T1 (also known as AML1-ETO) encoding the AML1-ETO fusion protein. RUNX1-CBF2T1 positive-AML blasts had eight-fold lower CEBPA RNA levels and undetectable C/EBP[alpha] protein levels compared with other subgroups of AML patients. Conditional expression of RUNX1-CBF2T1 in U937 cells downregulated CEBPA mRNA, protein and DNA binding activity. AML1-ETO appears to suppress C/EBP[alpha] expression indirectly by inhibiting positive autoregulation of the CEBPA promoter. Conditional expression of C/EBP[alpha] in AML1-ETO-positive Kasumi-1 cells results in neutrophilic differentiation. We suggest that restoring C/EBP[alpha] expression will have therapeutic implications in RUNX1-CBF2T1-positive leukemias., Author(s): Thomas Pabst [1]; Beatrice U. Mueller [1]; Nari Harakawa [1]; Claudia Schoch [2]; Torsten Haferlach [2]; Gerhard Behre [2]; Wolfgang Hiddemann [2]; Dong-Er Zhang [3]; Daniel G. Tenen (corresponding [...]

Published
2001
Full Text
View/download PDF

29. Comparison of non‐myeloablative and reduced‐intensity allogeneic stem cell transplantation in older patients with myelodysplastic syndromes

Author

Jentzsch, Madlen, primary, Döhring, Christine, additional, Linke, Richard, additional, Hille, Andrea, additional, Grimm, Juliane, additional, Pönisch, Wolfram, additional, Vucinic, Vladan, additional, Franke, Georg‐Nikolaus, additional, Behre, Gerhard, additional, Niederwieser, Dietger, additional, and Schwind, Sebastian, additional

Published
2019
Full Text
View/download PDF

30. Negative cross-talk between hematopoietic regulators: GATA proteins repress PU.1

Author

Pu Zhang, Behre, Gerhard, Jing Pan, Iwama, Atsushi, Wara-Aswapati, Nawarat, Radomska, Hanna S., Auron, Philip E., Tenen, Daniel G., and Zijie Sun

Subjects
Hematopoietic stem cells -- Research, Hematopoietic system -- Research, Leukemia research -- Analysis, Bone marrow cells -- Research, Science and technology
Abstract

The process through which multipotential hematopoietic cells commit to distinct lineages involves the induction of specific transcription factors. PU.1 (also known as Spi-1) and GATA-1 are transcription factors essential for the development of myeloid and erythroid lineages, respectively. Overexpression of PU.1 and GATA-1 can block differentiation in lineages in which they normally are down-regulated, indicating that not only positive but negative regulation of these factors plays a role in normal hematopoietic lineage development. Here we demonstrate that a region of the PU.1 Ets domain (the winged helix-turn-helix wing) interacts with the conserved carboxyl-terminal zinc finger of GATA-1 and GATA-2 and that GATA proteins inhibit PU.1 transactivation of critical myeloid target genes. We demonstrate further that GATA inhibits binding of PU.1 to c-Jun, a critical coactivator of PU.1 transactivation of myeloid promoters. Finally, PU.1 protein can inhibit both GATA-1 and GATA-2 transactivation function. Our results suggest that interactions between PU.1 and GATA proteins play a critical role in the decision of stem cells to commit to erythroid vs. myeloid lineages.

Published
1999

31. EVI2B is a C/EBP alpha target gene required for granulocytic differentiation and functionality of hematopoietic progenitors (vol 24, pg 705, 2017)

Author

Zjablovskaja, Polina, Kardosova, Miroslava, Danek, Petr, Angelisova, Pavla, Benoukraf, Touati, Wurm, Alexander A., Kalina, Tomas, Sian, Stephanie, Balastik, Martin, Delwel, Ruud, Brdicka, Tomas, Tenen, Daniel G., Behre, Gerhard, Fiore, Frederic, Malissen, Bernard, Horejsi, Vaclav, Alberich-Jorda, Meritxell, University of Pragues, Institute of Molecular Genetics ASCR, Institute of Molecular Genetics of the Czech Academy of Sciences (IMG / CAS), Czech Academy of Sciences [Prague] (CAS), National University of Singapore - Cancer Science Institute of Singapore, National University of Singapore (NUS), Cancer Biology Program Department of Medicine Beth Israel Deaconess Medical Center Harvard Medical School, Beth Israel Deaconess Medical Center [Boston] (BIDMC), Harvard Medical School [Boston] (HMS)-Harvard Medical School [Boston] (HMS), Centre d'Immunophénomique (CIPHE), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre d'Immunologie de Marseille - Luminy (CIML), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU)

Subjects
[SDV.IMM]Life Sciences [q-bio]/Immunology
Published
2019

32. Incubation of Immune Cell Grafts With MAX.16H5 IgG1 Anti-Human CD4 Antibody Prolonged Survival After Hematopoietic Stem Cell Transplantation in a Mouse Model for Fms Like Tyrosine Kinase 3 Positive Acute Myeloid Leukemia

Author

Hilger, Nadja, Müller, Claudia, Stahl, Lilly, Müller, Anne M., Zoennchen, Bianca, Dluczek, Sarah, Halbich, Christoph, Wickenhauser, Claudia, Gerloff, Dennis, Wurm, Alexander A., Behre, Gerhard, Kretschmer, Anna, Fricke, Stephan, and Publica

Subjects
Immunology, Graft vs Host Disease, Apoptosis, Graft vs Leukemia Effect, acute myeloid leukemia, Mice, immune system diseases, hemic and lymphatic diseases, Animals, Humans, Transplantation, Homologous, Original Research, anti-human CD4 antibody MAX.16H5, Mice, Knockout, graft-vs.-host disease, Hematopoietic Stem Cell Transplantation, graft-vs.-leukemia, Flow Cytometry, Prognosis, Disease Models, Animal, Leukemia, Myeloid, Acute, surgical procedures, operative, fms-Like Tyrosine Kinase 3, C3H / HeN, Immunoglobulin G, C3H/HeN, CD4 Antigens, 32D-FLT3ITD
Abstract

Despite the constant development of innovative therapeutic options for hematological malignancies, the gold-standard therapy regimen for curative treatment often includes allogeneic hematopoietic stem cell transplantation (HSCT). The graft-vs.-leukemia effect (GVL) is one of the main therapeutic goals that arises from HSCT. On the other hand, graft-vs.-host disease (GVHD) is still one of the main and most serious complications following allogeneic HSCT. In acute myeloid leukemia (AML), HSCT together with high-dose chemotherapy is used as a treatment option. An aggressive progression of the disease, a decreased response to treatment, and a poor prognosis are connected to internal tandem duplication (ITD) mutations in the Fms like tyrosine kinase 3 (FLT3) gene, which affects around 30% of AML patients. In this study, C3H/HeN mice received an allogeneic graft together with 32D-FLT3ITD AML cells to induce acute GVHD and GVL. It was examined if pre-incubation of the graft with the anti-human cluster of differentiation (CD) 4 antibody MAX.16H5 IgG1 prevented the development of GVHD and whether the graft function was impaired. Animals receiving grafts pre-incubated with the antibody together with FLT3ITD AML cells survived significantly longer than mice receiving untreated grafts. The observed prolonged survival due to MAX.16H5 incubation of immune cell grafts prior to transplantation may allow an extended application of additional targeted strategies in the treatment of AML.

Published
2018

35. Prognostic Impact of Blood MN1 Copy Numbers Before Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia

Author

Jentzsch, Madlen, primary, Bill, Marius, additional, Grimm, Juliane, additional, Schulz, Julia, additional, Beinicke, Stefanie, additional, Häntschel, Janine, additional, Goldmann, Karoline, additional, Pönisch, Wolfram, additional, Franke, Georg-Nikolaus, additional, Vucinic, Vladan, additional, Cross, Michael, additional, Behre, Gerhard, additional, Lange, Thoralf, additional, Niederwieser, Dietger, additional, and Schwind, Sebastian, additional

Published
2019
Full Text
View/download PDF

36. Prediction of Hepatic Complications after Allogeneic Haemotopoetic Stem Cell Transplantation Using Liver and Spleen Stiffness Measurement

Author

Franke, Georg-Nikolaus, primary, Weiße, Tina, additional, Petroff, David, additional, Beer, Sebastian, additional, Döhring, Christine, additional, Behre, Gerhard, additional, Fischer, Janett, additional, Lindner, Franziska, additional, Wiegand, Johannes, additional, Keim, Volker, additional, Niederwieser, Dietger, additional, and Karlas, Thomas, additional

Published
2018
Full Text
View/download PDF

39. Successful treatment of severe sinusoidal obstruction syndrome despite multiple organ failure with defibrotide after allogeneic stem cell transplantation: a case report

Author

Behre Gerhard, Theurich Sebastian, Christopeit Maximilian, and Weber Thomas

Subjects
Medicine
Abstract

Abstract Introduction We report a case of sinusoidal obstruction syndrome, a typical and life-threatening complication after allogeneic stem-cell transplantation, successfully treated with defibrotide despite massive multiple organ failure. Case presentation A 64-year-old Caucasian woman underwent allogeneic peripheral blood stem-cell transplantation from her human leukocyte antigen-identical sister against aggressive lymphoplasmocytoid immunocytoma. Seven days later, the patient developed severe sinusoidal obstruction syndrome according to the modified Seattle criteria. We initiated treatment with defibrotide. Despite early treatment, multiple organ failure with kidney failure requiring dialysis and ventilator-dependent lung failure aggravated the clinical course. Furthermore, central nervous dysfunction occurred as well as transfusion refractory thrombocytopenia. Conclusion As highlighted in our report, defibrotide is the most promising drug in the treatment of the formerly, almost lethal, severe sinusoidal obstruction syndrome to date. This is demonstrated very clearly in our patient. She improved completely, even after renal, cerebral and respiratory failure.

Published
2009
Full Text
View/download PDF

40. Graft-versus-lymphoma effect in a 64-year-old caucasian woman after allogeneic stem-cell transplantation: a case report

Author

Behre Gerhard, Weber Thomas, Theurich Sebastian, and Christopeit Maximilian

Subjects
Medicine
Abstract

Abstract Introduction The existence of a graft-versus-lymphoma effect is well established. When lacking a firm diagnosis, however, the clinician is challenged to to weigh the potential benefits of the graft-versus-lymphoma effect against potential dangers of graft-versus-host disease as well as against generalized (viral) infections. Case presentation We present evidence for a graft-versus-lymphoma effect in a 64-year-old caucasian woman with a transplanted peripheral blood-stem-cell graft from her Human Leukocyte Antigen-identical sister, and propose diagnostic measures to distinguish between graft-versus-host effect, and against viral disease or drug-induced reactions. Conclusion We were able to identify an allogeneic graft-reaction against progressive lymphoma alongside an erythema consistent with acute graft-versus-host disease of the skin. Establishing a firm diagnosis enabled us to decide against T-cell suppression (such as by using cyclosporine). Anti-lymphoma activity was favoured, by means of the allogeneic graft, local radiation and immunotherapy. This illustrates the importance of a sound differential diagnosis of erythema after allogeneic stem-cell transplantation, including assessment of viral disease of the affected tissue.

Published
2009
Full Text
View/download PDF

41. Correction to: EVI2B is a C/EBPα target gene required for granulocytic differentiation and functionality of hematopoietic progenitors

Author

Zjablovskaja, Polina, primary, Kardosova, Miroslava, additional, Danek, Petr, additional, Angelisova, Pavla, additional, Benoukraf, Touati, additional, Wurm, Alexander A., additional, Kalina, Tomas, additional, Sian, Stephanie, additional, Balastik, Martin, additional, Delwel, Ruud, additional, Brdicka, Tomas, additional, Tenen, Daniel G., additional, Behre, Gerhard, additional, Fiore, Fréderic, additional, Malissen, Bernard, additional, Horejsi, Vaclav, additional, and Alberich-Jorda, Meritxell, additional

Published
2018
Full Text
View/download PDF

42. ABR, a novel inducer of transcription factor C/EBPα, contributes to myeloid differentiation and is a favorable prognostic factor in acute myeloid leukemia

Author

Namasu, Carolina Yaeko, primary, Katzerke, Christiane, additional, Bräuer-Hartmann, Daniela, additional, Wurm, Alexander Arthur, additional, Gerloff, Dennis, additional, Hartmann, Jens-Uwe, additional, Schwind, Sebastian, additional, Müller-Tidow, Carsten, additional, Hilger, Nadja, additional, Fricke, Stephan, additional, Christopeit, Maximilian, additional, Niederwieser, Dietger, additional, and Behre, Gerhard, additional

Published
2017
Full Text
View/download PDF

43. High BAALC copy numbers in peripheral blood prior to allogeneic transplantation predict early relapse in acute myeloid leukemia patients

Author

Jentzsch, Madlen, primary, Bill, Marius, additional, Grimm, Juliane, additional, Schulz, Julia, additional, Goldmann, Karoline, additional, Beinicke, Stefanie, additional, Häntschel, Janine, additional, Pönisch, Wolfram, additional, Franke, Georg-Nikolaus, additional, Vucinic, Vladan, additional, Behre, Gerhard, additional, Lange, Thoralf, additional, Niederwieser, Dietger, additional, and Schwind, Sebastian, additional

Published
2017
Full Text
View/download PDF

44. Declined presentation the novel C/EBPalpha target gene EVI2B regulates myeloid differentiation and hematopoietic progenitor cell function

Author

Zjablovskaja, Polina, primary, Kardosova, Miroslava, additional, Danek, Petr, additional, Angelisova, Pavla, additional, Benoukraf, Touati, additional, Wurm, Alexander, additional, Kalina, Tomas, additional, Sian, Stephanie, additional, Balastik, Martin, additional, Delwel, Ruud, additional, Brdicka, Tomas, additional, Tenen, Daniel, additional, Behre, Gerhard, additional, Fiore, Fréderic, additional, Malissen, Bernard, additional, Horejsi, Vaclav, additional, and Alberich-Jorda, Meritxell, additional

Published
2017
Full Text
View/download PDF

45. Disruption of the C/EBPα—miR-182 balance impairs granulocytic differentiation

Author

Wurm, Alexander Arthur, primary, Zjablovskaja, Polina, additional, Kardosova, Miroslava, additional, Gerloff, Dennis, additional, Bräuer-Hartmann, Daniela, additional, Katzerke, Christiane, additional, Hartmann, Jens-Uwe, additional, Benoukraf, Touati, additional, Fricke, Stephan, additional, Hilger, Nadja, additional, Müller, Anne-Marie, additional, Bill, Marius, additional, Schwind, Sebastian, additional, Tenen, Daniel G., additional, Niederwieser, Dietger, additional, Alberich-Jorda, Meritxell, additional, and Behre, Gerhard, additional

Published
2017
Full Text
View/download PDF

46. Prognostic impact of the CD34+/CD38− cell burden in patients with acute myeloid leukemia receiving allogeneic stem cell transplantation

Author

Jentzsch, Madlen, primary, Bill, Marius, additional, Nicolet, Deedra, additional, Leiblein, Sabine, additional, Schubert, Karoline, additional, Pless, Martina, additional, Bergmann, Ulrike, additional, Wildenberger, Kathrin, additional, Schuhmann, Luba, additional, Cross, Michael, additional, Pönisch, Wolfram, additional, Franke, Georg-Nikolaus, additional, Vucinic, Vladan, additional, Lange, Thoralf, additional, Behre, Gerhard, additional, Mrózek, Krzysztof, additional, Bloomfield, Clara D., additional, Niederwieser, Dietger, additional, and Schwind, Sebastian, additional

Published
2017
Full Text
View/download PDF

47. EVI2B is a C/EBPα target gene required for granulocytic differentiation and functionality of hematopoietic progenitors

Author

Zjablovskaja, Polina, primary, Kardosova, Miroslava, additional, Danek, Petr, additional, Angelisova, Pavla, additional, Benoukraf, Touati, additional, Wurm, Alexander A, additional, Kalina, Tomas, additional, Sian, Stephanie, additional, Balastik, Martin, additional, Delwel, Ruud, additional, Brdicka, Tomas, additional, Tenen, Daniel G, additional, Behre, Gerhard, additional, Fiore, Fréderic, additional, Malissen, Bernard, additional, Horejsi, Vaclav, additional, and Alberich-Jorda, Meritxell, additional

Published
2017
Full Text
View/download PDF

49. High Expression of ZBTB7A at Diagnosis Associated with Inferior Outcome in Acute Myeloid Leukemia Patients Receiving Hematopoietic Stem Cell Transplantation

Author

Grimm, Juliane, primary, Jentzsch, Madlen, additional, Bill, Marius, additional, Schulz, Julia, additional, Schubert, Karoline, additional, Beinicke, Stefanie, additional, Haentschel, Janine, additional, Schuhmann, Luba, additional, Cross, Michael, additional, Vucinic, Vladan, additional, Poenisch, Wolfram, additional, Behre, Gerhard, additional, Franke, Georg-Nikolaus, additional, Niederwieser, Dietger, additional, and Schwind, Sebastian, additional

Published
2016
Full Text
View/download PDF

50. Biological Associations and Clinical Impact of Differential Expression of the Pre-Mir-29a/b-1 and Pre-Mir-29b-2/C Clusters in Acute Myeloid Leukemia

Author

Ramdohr, Florian, primary, Bill, Marius, additional, Jentzsch, Madlen, additional, Schubert, Karoline, additional, Grimm, Juliane, additional, Schulz, Julia, additional, Schuhmann, Luba, additional, Schmalbrock, Laura Katharina, additional, Bonifacio, Lynn Baquiran, additional, Beinicke, Stefanie, additional, Haentschel, Janine, additional, Poenisch, Wolfram, additional, Vucinic, Vladan, additional, Franke, Georg-Nikolaus, additional, Lange, Thoralf, additional, Cross, Michael, additional, Behre, Gerhard, additional, Niederwieser, Dietger, additional, and Schwind, Sebastian, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results